pharmaceuticals

pharmaceuticals Articles

GlycoMimetics shares were crushed on Monday after the firm announced late-stage results from its sickle cell disease trial in conjunction with Pfizer.
Merck released better than expected second-quarter financial results before the markets opened on Tuesday.
Pfizer and Merck are each scheduled to release their second-quarter financial results early Tuesday. These are just a couple of the Dow Jones industrials that are reporting this week, but they make...
Lexicon Pharma shares were absolutely crushed on Monday after it was announced that Sanofi would be ending its partnership with the firm.
Mylan released its second-quarter financial results before the markets opened on Monday. The pharma giant also announced a major update to its business involving Pfizer and that CEO Heather Bresch is...
The July 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Acadia Pharmaceuticals shares dropped on Tuesday after the firm announced results from its late-stage study for the treatment of adult schizophrenia patients.
Johnson & Johnson shares traded lower despite beating earnings. It turns out that there are some issues outside of earnings that shareholders are having a hard time quantifying.
24/7 Wall St. has picked a few biotech standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus analyst price target.
Johnson & Johnson retreated though it reported better than expected second-quarter before the markets opened on Tuesday.
Johnson & Johnson is scheduled to report its most recent quarterly results before the markets open on Tuesday.
The June 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were increased.
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia.
24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus analyst price target.